ONCOLOGY Vol 24 No 3_Suppl_2

home / journals / oncology / oncology-vol-24-no-3_suppl_2
Tailoring Treatment for Multiple Myeloma Patients With Relapsed and Refractory Disease

Tailoring Treatment for Multiple Myeloma Patients With Relapsed and Refractory Disease

Paul G. Richardson, MD;Jacob Laubach, MD;Constantine S. Mitsiades, MD, PhD;Robert L. Schlossman, MD;Deborah Doss, BSN, RN;Kathleen Colson, RN;Mary L. Mckenney, NP;Kimberly Noonan, NP;Irene M. Ghobrial, MD;Nikhil C. Munshi, MD;Kenneth C. Anderson, MD
March 16th 2010
Article

Responses to treatment of relapsed and refractory multiple myeloma are characteristically short, and median survival is as brief as 6 months. Although prognostic factors in the context of relapsed and refractory disease require further characterization, high-risk patients include those with certain cytogenetic abnormalities, high β2-microglobulin, and low serum albumin.

Site Logo

Best Practices in the Management of Newly Diagnosed Multiple Myeloma Patients Who Will Not Undergo Transplant

Ruben Niesvizky, MD;Morton Coleman, MD;Tomer Mark, MD
March 16th 2010
Article

No survival advantage of autologous stem cell transplantation (ASCT) has been documented for patients older than 65 years, and in the era of thalidomide (Thalomid), bortezomib (Velcade), and len­alidomide (Revlimid), ASCT has a diminished role in the front-line treatment of older patients with myeloma.

Site Logo

Tailoring Initial Treatment for Newly Diagnosed, Transplantation-Eligible Multiple Myeloma

Edward A. Stadtmauer, MD
March 15th 2010
Article

High-dose melphalan (Alkeran) and autologous stem cell transplantation are commonly incorporated into the initial line of therapy for patients newly diagnosed with multiple myeloma.